


SIDDS 2023

Seoul International Digestive Disease Symposium 2023



April 8-9, 2023 Hybrid congress

Name	Nayoung Kim
Affiliation	Seoul National University College of Medicine
	Seoul National University Bundang Hospital
Country	Republic of Korea
Major Field	Gastroenterology
Contact No.	010-2291-1987

Educational Background

Dr. Nayoung Kim graduated from Seoul National University College of Medicine in 1986, and earned Ph.D. degree in 1991 in Seoul National University College of Medicine

Professional Experience

She stayed at Gastrointestinal Motility Laboratory in Brown University, USA as a Research Fellow (1994-1995). She also worked at Membrane Biology Laboratory, UCLA Medical School, USA as a Research Scholar (1999-2002). Now, she is a professor at the Department of Internal Medicine, Seoul National University Bundang Hospital and Seoul National University College of Medicine, Korea since 2003. She actively participates in the Korean Academic Society activities and performed a good job as Deputy Editor of Journal of Neurogastroenterology and Motility (2011-2015). In addition, she was a Congress Chairwoman of Korean Society of Neurogastroenterology and Motility from April 2015 till April 2017. She was Vice President of Korea Federation of Women Science and Technology Association (KOFWST) from Jan. 2018 till Jan. 2020. She has about 250 SCI publications in the various GI areas as a first author or corresponding author and the citation number was over 26,368 times (google in Feb. 14th, 2023). She received Marshall Warren Lectureship Award on Nov. 15th, 2018 from JGH Foundation at APDW 2018. Her experience and publication are also available from: http://orcid.org/0000-0002-9397-0406.

Other Experience and Professional Memberships

The Senate of Seoul National University since Nov. 2020.

Member of National Academy of Medicine of Korea since Feb. 2015.

Main Scientific Publications

Papers as a corresponding author

1. Kim HJ, <u>Kim N</u>, Kim HW, et al. Promising aberrant DNA methylation marker to predict gastric cancer development in individuals with family history and long-term effects of *H. pylori* eradication on DNA methylation. Gastric Cancer 2021;24:302-313.



SIDDS 2023



Seoul International Digestive Disease Symposium 2023

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 8-9, 2023 Hybrid congress

- 2. Shin CM, <u>Kim N</u>, Park JH, et al. Changes in gastric corpus microbiota with age and after *Helicobacter pylori* eradication: A long-term follow-up study. Front Microbiol 2021;11:621879
- 3. Shin CM, Park K, <u>Kim N</u>, et al. rs2671655 single nucleotide polymorphism modulates the risk for gastric cancer in *Helicobacter pylori*—infected individuals: A genome-wide association study in the Korean population. Gastric Cancer. 2022;25:573-585.
- 4. Lee JY, <u>Kim N</u>, Yoon H, et al. A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of DA-9701 (Motilitone) in patients with constipation-type irritable bowel syndrome and functional dyspepsia overlap: A pilot study. J Neurogastroenterol Motil.. 2022;28:265-275.
- 5. Song CH, <u>Kim N</u>, Nam RH, et al. Combination treatment with 17β-estradiol and anti-PD-L1 suppresses MC38 tumor growth by reducing PD-L1 expression and enhancing M1 macrophage population in MC38 colon tumor model. Cancer Lett. 2022;543:215780.

Books as an Editor

1. Helicobacter pylori by Springer (p556) in 2016 Sex/Gender-Specific Medicine in the Gastrointestinal Diseases by Springer (p468) in 2022